perenostobart

Home
Ligands
perenostobart

GtoPdb Ligand ID: 12103

Synonyms: SRF-617 | SRF617

Comment: Perenostobart is a monoclonal antibody that targets ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1/CD39). Based on analysis using the amino acid (aa) sequences provided in the INN documentation and patented aa sequences (via NCBI Blast: protein), perenostobart would appear to map to Surface Oncology's clinical lead anti-CD39 mAb SRF617. Surface Oncology claim anti-CD39 mAbs in patent US10738128B2 [1]. SRF617 is a fully human mAb that was designed to inhibit the enzymatic activity of ENTPD1/CD39.

Summary
Biological activity
Clinical data
References
Immunopharmacology

Immunopharmacology Comments
Blocking ENTPD1 activity is a mechanism that is being exploited to disrupt the ATP/adenosine immune checkpoint pathway that promotes adenosine-induced immunosuppression in the tumour microenvironment. Perenostobart can be considered as an immunostimulat that restores the immune response against cancer cells.

Immunopharmacology Comments

Blocking ENTPD1 activity is a mechanism that is being exploited to disrupt the ATP/adenosine immune checkpoint pathway that promotes adenosine-induced immunosuppression in the tumour microenvironment. Perenostobart can be considered as an immunostimulat that restores the immune response against cancer cells.